Key result
Suppression of prostacyclin production with aspirin did not augment initial platelet deposition at the human microvascular anastomosis.
In a human ex vivo model, initial platelet deposition at microvascular anastomoses appears independent of cyclooxygenase pathways, as aspirin suppression of prostacyclin did not alter deposition.
Answers are grounded in this paper and cite their sources.
Ex vivo suppression of prostacyclin did not alter early platelet deposition; leaves open whether COX pathways affect clinical microvascular patency.
The human microvascular anastomosis represents a localized environment with strongly thrombotic tendencies. In previous studies, an increase in initial platelet deposition at a human ex vivo anastomosis was measured. It is postulated that this increase in anastomotic platelet deposition was due to a reduction in anastomotic prostacyclin production as a consequence of local endothelial cell injury or loss. Instead, in this study, an increase in anastomotic prostacyclin production over unsutured controls (control 1093 +/- 222 pg/ml of 6-keto prostaglandin F (PGF) 1-alpha, n=21; anastomosis 2494 +/- 414, n=21, mean +/- 1 SEM, p=0.005) is demonstrated. Anastomotic prostacyclin production was augmented by addition of arachidonic acid (0.1 mM) (39,000 +/- 11,300 pg/ml of 6-keto PGF 1-alpha, n=7, p<0.001) and suppressed by the preincubation of vessel segments with aspirin in a dose-dependent fashion (1mM) (83+/-22 pg/ml of 6-keto PGF 1-alpha, n=21, p<0.001); aspirin (0.1 mM) (312 +/- 56 pg/ml of 6-keto PGF 1-alpha, n=7, p<0.001). In further studies using a perfusion apparatus of human blood pumped through human placental artery segments, suppression of prostacyclin production did not augment initial platelet deposition (control anastomosis 4.9 +/- 2.2 x10(6) platelets per cm2, aspirin treatment 6.0 +/- 2.8 x 10(6) platelets per cm2, n=5, mean +/- 1 SEM, p>0.05). Suppression of platelet function with aspirin (0.1 mM) also did not decrease initial platelet deposition onto the anastomosis (5.8 +/- 2.8 x 10(6) platelets per cm2, n=r, p>0.05). In this model system, initial platelet deposition at the anastomosis may not be dependent upon cyclooxygenase pathways.
No takes yet. Share an insight, caveat, or question.
Restifo et al. (1996) studied Microvascular anastomosis. Aspirin vs. Control anastomosis was evaluated on Initial platelet deposition (p=>0.05). Suppression of prostacyclin production with aspirin did not augment initial platelet deposition at the human microvascular anastomosis.
Synapse has enriched 10 related papers. Consider them for comparative context: